A total of ∼200 million people worldwide are thought to be carriers of hepatitis B virus (HBV), which causes acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Vaccination with blood-derived and genetically engineered subunit HBV surface antigen (HBsAg) vaccine (SHV) is used to prevent HBV infection in high-risk groups. Oka varicella vaccine has been successfully used to confer active immunity without major adverse reactions in immunocompromised patients [1] , and it is approved for general use in the United States. Oka varicella vaccine induces immunity to varicella-zoster virus (VZV) infection, which is characterized as a humoral antibody response and cell-mediated immunity, especially delayed-type hypersensitivity (DTH), by the cutaneous reaction with the varicella skin test antigen [2] . Oka varicella vaccine has been used to express foreign genes, such as Epstein-Barr virus glycoprotein [3] and herpes simplex virus glycoprotein D [4] . We have constructed and characterized a recombinant Oka varicella vaccine (ROka)
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In this study, using HBsAg as an immunologic marker, we characterized the immunogenicity of Oka varicella vaccine as a vaccine vector. HBsAg of both ROka and SHV was derived from the same HBsAg gene (adr subtype) [5, 6] . We compared the humoral and cell-mediated immune responses to HBsAg induced by ROka and by SHV. Antibody induced by the immunization groups was compared by using glycosylated and nonglycosylated HBsAg and its constituent 16 species of the peptides. The discrepancy of antibody to HBsAg and the linear "a" loop epitope [7] suggested the enhanced recognition of the conformational epitope of HBsAg [8] by ROka immunization. We also characterized an inverse relationship between reduction of antibody production and induction of DTH, representing the macrophage-Th1 cell-type response by the Oka varicella vaccine vector.
Materials and Methods
Vaccine. SHV for human use was supplied by the Research Foundation for Microbial Diseases of Osaka University, Suita, Japan. SHV contains 10 mg of HBsAg derived from yeast with alum. ROka was prepared from infected human embryonic lung cells, as described elsewhere [5] . Guinea pigs were immunized subcutaneously with 1 dose of SHV or 15,000 pfu of ROka.
Antigens. Nonglycosylated HBsAg derived from yeast was supplied by the Research Foundation for Microbial Diseases, Osaka University. Glycosylated HBsAg derived from the sera of HBV carriers [9] was prepared from an HBsAg-positive control kit (International Reagent, Kobe, Japan) for the reversed passive hemagglutination (RPHA) test [5] . VZV gE:gI was purified by ap- plication of Oka varicella vaccine-infected cell lysate to an affinity column coupled with a monoclonal antibody against gE [10, 11] .
Vaccination and immunization schedule. Female guinea pigs (Yodo strain) weighing ∼280 g (Japan Rabbit Center, Ibaraki, Japan) were used for immunization with SHV or infection with ROka [2, 5, 11] . ROka and SHV were used as the primary and booster HBsAg vaccines for 5 guinea pigs with the 3 combinations SHV-SHV, SHV-ROka, and ROka-SHV at 4-week intervals. PBS was used as a control vaccine for immunization as the primary and booster vaccines in the same schedule (PBS-PBS). Immune responses to HBsAg and gE:gI were evaluated 4 weeks after the 2d vaccination.
Lymphocyte proliferation assay. Mononuclear cells from spleens were separated by use of ficoll-hypaque density gradients and resuspended in complete medium (RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum and M 2-Ϫ6 5 ϫ 10 mercaptoethanol) for lymphocyte proliferation [11] . In brief, 10 mL of purified HBsAg (100 mg/mL) or gE:gI (100 mg/mL) was plated onto each well of a 96-well plate, and 50 mL of mononuclear cells ( cells/mL) was added. The mixtures were cultivated in trip- Cutaneous reaction. Guinea pigs were injected intradermally at 3 sites on their backs with 0.1 mL of HBsAg (1 mg) and gE:gI (3.2 mg) after hair was removed with a chemical depilatory [2, 11] . The erythematous area was measured at 8, 24, and 48 h, and its area was regarded as an ellipse and expressed by the following formula: area = p[(long diameter ϫ short diameter)/4].
Antibody assay. Sera were tested for HBsAg and gE:gI by PHA test (International Reagent) and ELISA, respectively [5, 11] . Sera were diluted 100 times with PBS containing 2% skim milk and were applied to each well, which had been treated with 0.5 mg of gE:gI, to determine the antibody titer to gE:gI in the ELISA. Then anti-guinea pig IgG goat IgG conjugated with peroxidase (whole molecule; Organon Teknika/Cappel, Durham, NC) was distributed to the wells, and the reaction was visualized by use of the substrate solution of the hepatitis A total immunoglobulin-EIA kit (Denka Seiken, Niigata, Japan). Antibody to HBsAg was measured by the ELISA, using HBsAg derived from the sera of HBV carriers (glycosylated HBsAg) and yeast (nonglycosylated HBsAg) [6, 9] . HBsAg was coated in wells at a concentration of 1 mg/50-mL well, and a further reaction was done as described above.
Peptide ELISA. To determine the antigenic epitope of HBsAg, 16 species of peptides constituting the whole part of HBsAg were prepared in 96-well plates of the Multipin noncleavable peptide synthesis kit (Chiron, San Diego) in accordance with the manufacturer's instructions. The antibody titer to each peptide was determined as described for the ELISA.
Statistical analysis. The statistical significance of all data was assessed by an unpaired Student's t test.
was considered P ! .05 statistically significant.
Results
Immune response to VZV gE:gI. We compared the immune response to gE:gI among 4 immunization groups (table 1, figure  1 ). Because SHV-SHV and PBS-PBS immunization groups were not immunized with VZV, no immune response to gE:gI was observed. SHV-ROka and ROka-SHV immunization induced similar lymphocyte proliferation responses and cutaneous reactions to gE:gI (figure 1). The cutaneous reaction continued 48 h after inoculation and represented typical DTH over the time course. As shown in table 1, SHV-ROka immunization induced significantly higher antibody titers against gE:gI than ROka-SHV immunization ( ). This difference may be P ! .01 caused by the decline in antibody titer 4-8 weeks after immunization with ROka.
Immune response to HBsAg. We compared the immunogenicity of ROka and SHV (table 1, figure 1) . The PBS-PBS combination did not induce any immune response to HBsAg. The 3 immunization combinations induced a similar level of lymphocyte proliferation ( figure 1C) . The cutaneous reaction to HBsAg in the SHV-SHV and ROka-SHV groups showed a typical Arthus-type reaction over the time course, and both immunization groups, in contrast to the SHV-ROka group, failed to induce reactivity at 24 and 48 h ( ). SHV-ROka P ! .01 immunization induced a strong cutaneous reaction to HBsAg at 24 and 48 h, and the reaction profile during the time course was similar to that of gE:gI observed in ROka immunization. Thus, only SHV-ROka immunization induced the cutaneous reaction characteristic of DTH against HBsAg.
Antibody response to HBsAg. Table 1 shows the results of antibody production to HBsAg and its constituent peptides. Antibody to HBsAg assessed by the RPHA, using serum-derived HBsAg, was significantly higher in the SHV-SHV group than in the other combinations ( ). Glycosylated and non-P ! .01 glycosylated HBsAg were used as test antigens to measure antibody to HBsAg; by ELISA of the combinations, SHV-SHV immunization induced the strongest antibody production to glycosylated ( ) and nonglycosylated HBsAg ( ), P ! .05 P ! .01 consistent with the RPHA result.
All groups immunized with HBsAg vaccines responded to the major "a" loop epitope of HBsAg; little response to the other peptides was observed. There was no significant difference in the profile of the antibody response to each peptide among the 3 HBsAg immunization groups. However, antibody titer to the major "a" loop epitope of HBsAg was highest in the SHV-SHV group ( ) and was comparable in the ROka-SHV P ! .05 and SHV-ROka groups.
There was no significant difference in the ratio of antibody to nonglycosylated and glycosylated HBsAg among the 3 groups. However, the ratio of antibody to the "a" loop peptide versus the nonglycosylated or glycosylated HBsAg was smallest in the SHV-ROka immunization group and was significantly lower in the SHV-ROka group than in the SHV-SHV group (
). This suggests that antibodies in the SHV-ROka im-P ! .05 munization group may recognize an epitope other than the linear "a" loop epitope to attain the total antibody response to the whole HBsAg. The difference may not be due to the glycosylation of HBsAg, as shown by the comparison of the antibody ratios between glycosylated and nonglycosylated HBsAg. Therefore, the supplementary recognition of the conformational epitope may explain the discrepancy of the ratio of antibody to the "a" loop peptide versus HBsAg, suggesting enhanced recognition of the conformational epitope in addition to the linear "a" epitope of HBsAg in the SHV-ROka immunization group.
Discussion
We characterized the immunogenicity of ROka as Oka varicella vaccine vector by using HBsAg as a marker of immune response in a guinea pig model. VZV gE:gI is a major target of the immune response in VZV infection, and the cutaneous reaction to the VZV antigen, including gE:gI, is induced in guinea pigs [2, 11] . SHV-ROka immunization induced DTH and antibody production to HBsAg and gE:gI. In contrast, SHV-SHV immunization produced the highest antibody production to HBsAg without DTH. The second booster immunization with ROka and SHV caused a typical example of immune deviation [12] between DTH and antibody response in these 2 groups.
Macrophages and Langerhans cells in the skin mediate the cutaneous reaction [13] . VZV grows in the skin. Therefore, the immune response mediated by cutaneous macrophages, including Langerhans and dendritic cells, may induce the strong cutaneous reaction. They may release interleukin-12 from stimulation by the antigens expressed in VZV-infected cells and may activate Th1 cells, resulting in the induction of a Th1-dominant response, such as DTH [12] [13] [14] . Thus, expression of viral antigens in the infected cells may cause a significant difference in the process of antigen recognition, such as the enhanced recognition of the conformational epitope and the induction of DTH, as shown in this study.
A Th1-type response is important in viral clearance and recovery from chronic hepatitis B [15] . ROka induced a Th1-dominant immune response to HBsAg. Therefore, this recombinant vaccine may help improve the immune status to HBV in persons with chronic hepatitis B. However, because the Th1 response is also important in the pathogenesis of liver cell injury, liver function should be carefully monitored. Altogether, vaccination with this recombinant varicella vaccine may improve the immune status of patients with chronic hepatitis B and thereby have a beneficial effect in reducing hepatitis activity.
This study revealed that the Oka varicella vaccine vector induced a VZV-type immune response to HBsAg, especially a Th1-type response, as assessed by reduced antibody production and DTH induction. The Oka varicella vaccine vector may induce a Th1-type response to the foreign antigen. This response is beneficial in improving the clinical status of patients such as those with chronic hepatitis B. Furthermore, the introduction of cellular immunity by this live recombinant vaccine may be useful for future vaccine development, especially for human immunodeficiency and hepatitis C viruses, in which the humoral immunity produced by the traditional approach of the pure protein vaccine is not effective.
